Advances in Glycoconjugate Vaccines and Nanovaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1334

Special Issue Editors


E-Mail Website
Guest Editor
Department of Drug Sciences, School of Pharmacy, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy
Interests: syndetic organic chemistry; medicinal chemistry; chemical biology; protein engineering; biocatalysis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy
Interests: rational design and analytical characterization by MS-based approaches of naturally and synthetically glycosylated proteins (e.g., glycoconjugate vaccines, monoclonal antibodies) and nanoparticles

Special Issue Information

Dear Colleagues,

Glycoconjugate vaccines, obtained by linking carbohydrates to protein carriers, have had a critical role in fighting infectious diseases. RNA-based technologies are a novel approach to developing anti-infection and anti-cancer vaccines from preclinical to clinical stages. They are particularly effective in targeting carbohydrates, one of the most important classes of surface antigens, and can also be used as adjuvants to promote immunostimulant effects.

While traditional conjugation approaches and using soluble proteins as carriers have been common, recent advancements have been made in the field. New glycosylation strategies have been established, and nanotechnology is increasingly used in vaccine development. Chemically glycosylated organic and inorganic nanoparticles are being used to enhance immunostimulation and delivery. Finally, the complexity of glycoconjugate structures requires suitable analytical methods to support their design and development.

We are pleased to invite you to contribute to this Special Issue, which will focus on recent advancements in the design, development, and characterization of glycosylated proteins and nanoparticles as potential vaccines. The Special Issue is open to original research articles and reviews on antigenic/immunogenic oligosaccharides or new glyco-derivatives, as well as pre-clinical and clinical studies on anti-infection or anticancer glyco-(nano)vaccines. Investigations on analytical approaches to support the design and production of glycoconjugates will also be considered.

We look forward to receiving your contributions.

Prof. Dr. Marco Terreni
Dr. Sara Tengattini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glycoconjugate vaccines
  • infection diseases
  • anticancer vaccines
  • glycosylated nanovaccines
  • antigenic saccharides
  • conjugation chemistry
  • glycoconjugate characterization
  • dual-acting vaccines
  • glycosylated nanoparticles

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 5943 KiB  
Article
Modeling 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) Chemistry to Design Glycoconjugate Vaccines with Desired Structural and Immunological Characteristics
by Rebecca Nappini, Renzo Alfini, Salvatore Durante, Laura Salvini, Maria Michelina Raso, Elena Palmieri, Roberta Di Benedetto, Martina Carducci, Omar Rossi, Paola Cescutti, Francesca Micoli and Carlo Giannelli
Vaccines 2024, 12(7), 707; https://doi.org/10.3390/vaccines12070707 - 24 Jun 2024
Viewed by 970
Abstract
Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing immunological memory. Glycoconjugate vaccines have been successful in reducing the [...] Read more.
Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing immunological memory. Glycoconjugate vaccines have been successful in reducing the burden of different diseases globally. However, many pathogens still require a vaccine, and many of them display a variety of glycans on their surface that have been proposed as key antigens for the development of high-valency glycoconjugate vaccines. CDAP chemistry represents a generic conjugation strategy that is easily applied to PS with different structures. This chemistry utilizes common groups to a large range of PS and proteins, e.g., hydroxyl groups on the PS and amino groups on the protein. Here, new fast analytical tools to study CDAP reaction have been developed, and reaction conditions for PS activation and conjugation have been extensively investigated. Mathematical models have been built to identify reaction conditions to generate conjugates with wanted characteristics and successfully applied to a large number of bacterial PSs from different pathogens, e.g., Klebsiella pneumoniae, Salmonella Paratyphi A, Salmonella Enteritidis, Salmonella Typhimurium, Shighella sonnei and Shigella flexneri. Furthermore, using Salmonella Paratyphi A O-antigen and CRM197 as models, a design of experiment approach has been used to study the impact of conjugation conditions and conjugate features on immunogenicity in rabbits. The approach used can be rapidly extended to other PSs and accelerate the development of high-valency glycoconjugate vaccines. Full article
(This article belongs to the Special Issue Advances in Glycoconjugate Vaccines and Nanovaccines)
Show Figures

Figure 1

Back to TopTop